[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100559324":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":22,"locations":23,"responsibleParty":58,"collaborators":22,"id":62,"slug":22,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":22,"eligibilityCriteria":67,"healthyVolunteers":63,"sex":68,"minAge":69,"maxAge":70,"enrollmentInfo":71,"targetDuration":22,"studyType":74,"phases":75,"briefSummary":77,"conditions":78,"keywords":22,"overallStatus":26,"whyStopped":22,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":72},{"fullName":5,"class":6},"Cell Origin Biotech (Hangzhou) Co., Ltd.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"SY001 Targets Mesothelin positive solid tumors in a Dose-increasing Setting","EXPERIMENTAL","Patients with mesothelin-positive ovarian cancer were treated with an SY001 injection in combination with an anti-PD-1 antibody. Patient 001 received 1109 SY001 CAR-pMACs via intravenous injection. Following a two-month period in which the treatment's safety was confirmed, this patient underwent another two does of 1109 SY001 cells on both day 1 and day 3. Prior to the CAR-pMACs infusion on day 1, a PD1 antibody Tislelizumab Injection was administered. In the case of the patient 002, SY001 treatment was delivered intravenously on three occasions: day 1, day 3, and day 5. The same as the first patient's protocol, Tislelizumab was given prior to the CAR-pMACs on day 1.",[13],"Drug: SY001",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","SY001","PBMC-derived anti-mesothelin Cheimeric Antigen Receptor macrophages",[9],[21],"CAR-pMAC",null,[24,44],{"facility":25,"status":26,"city":27,"state":28,"zip":29,"country":30,"countryCode":31,"cosmosGeoPoint":32,"geoPoint":37,"contacts":38},"The First Affiliated Hospital, Zhejiang University School of Medicine","RECRUITING","Hangzhou","Zhejiang","310000","China","CN",{"type":33,"coordinates":34},"Point",[35,36],120.16142,30.29365,{"lat":36,"lon":35},[39],{"name":40,"role":41,"phone":42,"phoneExt":22,"email":43},"Jianhua Qian, PHD","CONTACT","17816142153","qianjianhua@zju.edu.cn",{"facility":45,"status":46,"city":47,"state":22,"zip":22,"country":30,"countryCode":31,"cosmosGeoPoint":48,"geoPoint":52,"contacts":53},"Linyi Cancer Hospital","NOT_YET_RECRUITING","Linyi",{"type":33,"coordinates":49},[50,51],118.34278,35.06306,{"lat":51,"lon":50},[54],{"name":55,"role":41,"phone":56,"phoneExt":22,"email":57},"Xiumin Li","+86 18868115772","Lyzlyylxm@163.com",{"type":59,"investigatorFullName":60,"investigatorTitle":61,"investigatorAffiliation":5,"oldNameTitle":22,"oldOrganization":22},"PRINCIPAL_INVESTIGATOR","Xudong Wang","manager","100559324",false,"NCT06562647","SY001 Targets Mesothelin in a Single-arm, Dose-increasing Setting in Subjects With Advanced Solid Tumors","An Exploratory Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Initial Efficacy of SY001 Injection Targets Mesothelin in a Single-arm, Dose-increasing Setting in Subjects With Advanced Solid Tumors","Inclusion Criteria:\n\n1. Patients with pathologically diagnosed advanced ovarian cancer\u002Fpancreatic cancer who have failed at least 1 prior lines treatment, and tumor tissue samples were positive for mesothlin IHC staining;\n2. According to the RECIST 1.1, there is measurable tumor lesions (non-lymph node lesion 10mm in length or lymph node lesion 15mm in diameter measured by CT or MRI, with scan layer thickness 5mm);\n3. Eastern Cooperative Oncology Group (ECOG) score of 2 and satisfactory major organ functions;\n4. Estimated life expectancy \\>3 months;\n5. Female patients of childbearing age must undergo a serum pregnancy test at screening and prior to pretreatment and the results must be negative, and are willing to use a very effective and reliable method of contraception within 1 year after the last study treatment.\n\nExclusion Criteria:\n\n1. Pregnant or lactating women;\n2. Any uncontrollable active infection, including but not limited to active tuberculosis, HBV infection;\n3. Patients who have a history of other mesothelin-targeting therapy;\n4. Patients who have a history of autoimmune disease;\n5. The investigator assessed that the patient was unable or unwilling to comply with the requirements of the study protocol.","FEMALE","18 Years","75 Years",{"count":72,"type":73},2,"ESTIMATED","INTERVENTIONAL",[76],"NA","Single-arm, dose-increasing setting study of CAR macrophages in Mesothelin overexpressing solid tumors.",[79,80],"Treatment Related Cancer","Ovarian Cancer","2026-02-12",{"date":83,"type":84},"2026-02-13","ACTUAL",{"date":86,"type":84},"2023-04-12",{"date":88,"type":73},"2027-12",{"name":5,"class":6}]